Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 439,091 shares of the medical equipment provider's stock after buying an additional 11,329 shares during the period. Hsbc Holdings PLC owned about 0.22% of Zimmer Biomet worth $46,388,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. J. Safra Sarasin Holding AG boosted its holdings in Zimmer Biomet by 87.6% during the 4th quarter. J. Safra Sarasin Holding AG now owns 25,189 shares of the medical equipment provider's stock valued at $2,661,000 after acquiring an additional 11,765 shares during the period. Stifel Financial Corp lifted its position in shares of Zimmer Biomet by 10.8% during the fourth quarter. Stifel Financial Corp now owns 96,032 shares of the medical equipment provider's stock worth $10,144,000 after purchasing an additional 9,341 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Zimmer Biomet by 111.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 16,458 shares of the medical equipment provider's stock valued at $1,738,000 after purchasing an additional 8,691 shares in the last quarter. Natixis acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $12,881,000. Finally, Ossiam increased its stake in Zimmer Biomet by 6.4% during the 4th quarter. Ossiam now owns 6,548 shares of the medical equipment provider's stock worth $692,000 after buying an additional 396 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Finally, Truist Financial reaffirmed a "hold" rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Stock Performance

ZBH traded down $0.04 during trading on Friday, hitting $101.46. 1,661,962 shares of the stock were exchanged, compared to its average volume of 1,669,704. The firm has a market capitalization of $20.07 billion, a P/E ratio of 22.80, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96. The stock has a fifty day moving average price of $105.81 and a two-hundred day moving average price of $106.59. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business posted $2.20 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.